Cargando…

Is the Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Ratio a Marker of Sonographic Septations in Pleural Infection?

Detalles Bibliográficos
Autores principales:	Yasuma, Taro, D’Alessandro-Gabazza, Corina N., Kobayashi, Tetsu, Gabazza, Esteban C., Fujimoto, Hajime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111981/ https://www.ncbi.nlm.nih.gov/pubmed/36413774 http://dx.doi.org/10.1164/rccm.202210-1916LE

Ejemplares similares

Response of Lung Microbiota to Changes of Pulmonary Innate Immunity under Healthy Conditions
por: Yasuma, Taro, et al.
Publicado: (2021)

The Need for a CYFRA 21-1 Cutoff Value to Predict Clinical Progression of IPF in Clinical Practice
por: Fujimoto, Hajime, et al.
Publicado: (2022)

Microbial Burden-associated Cytokine Storm May Explain Nonresolving Acute Respiratory Distress Syndrome in Patients with COVID-19
por: Yasuma, Taro, et al.
Publicado: (2022)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

No Strong Evidence for Ruling Out the Role of Coagulation in Long-Term Disability after Critical Illness
por: Yasuma, Taro, et al.
Publicado: (2021)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Inflammation during Pregnancy Predisposes to Childhood Asthma by Altering Long Noncoding RNA Expression
por: Kobayashi, Tetsu, et al.
Publicado: (2023)

Role of Matrix Metalloproteinase-2 in Eosinophil-Mediated Airway Remodeling
por: Kuwabara, Yu, et al.
Publicado: (2018)

Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection
por: Bédat, Benoît, et al.
Publicado: (2019)

Subcritical Water Extracts from Agaricus blazei Murrill’s Mycelium Inhibit the Expression of Immune Checkpoint Molecules and Axl Receptor
por: Yasuma, Taro, et al.
Publicado: (2021)

β(2) adrenergic agonist suppresses eosinophil-induced epithelial-to-mesenchymal transition of bronchial epithelial cells
por: Kainuma, Keigo, et al.
Publicado: (2017)

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
por: Fujiwara, Atsushi, et al.
Publicado: (2018)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
por: Tucker, Torry A., et al.
Publicado: (2021)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Prognostic Value of CXCL12 in Non-Small Cell Lung Cancer Patients Undergoing Tumor Resection
por: Kogue, Yurie, et al.
Publicado: (2023)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Factors leading to failure to diagnose pulmonary malignant tumors using endobronchial ultrasound with guide sheath within the target lesion
por: Nishii, Yoichi, et al.
Publicado: (2019)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
por: Nishimura, Tadashi, et al.
Publicado: (2021)

Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report
por: Nishimura, Tadashi, et al.
Publicado: (2021)

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Activated protein C modulates the proinflammatory activity of dendritic cells
por: Matsumoto, Takahiro, et al.
Publicado: (2015)

Transforming Growth Factorβ1 Overexpression Is Associated with Insulin Resistance and Rapidly Progressive Kidney Fibrosis under Diabetic Conditions
por: D’Alessandro, Valeria Fridman, et al.
Publicado: (2022)

Protein S is Protective in Acute Lung Injury by Inhibiting Cell Apoptosis
por: Baffour Tonto, Prince, et al.
Publicado: (2019)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
por: Fujiwara, Takumi, et al.
Publicado: (2020)

Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression
por: Inoue, Ryo, et al.
Publicado: (2023)

Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice
por: Kida, Yoshifumi, et al.
Publicado: (2023)

Smart watch-based coaching with tiotropium and olodaterol ameliorates physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2017)

Renal Injury during Long-Term Crizotinib Therapy
por: Yasuma, Taro, et al.
Publicado: (2018)

Ligand binding modulates the structural dynamics and activity of urokinase-type plasminogen activator: A possible mechanism of plasminogen activation
por: Kromann-Hansen, Tobias, et al.
Publicado: (2018)

Protective Role of Recombinant Human Thrombomodulin in Diabetes Mellitus
por: Okano, Yuko, et al.
Publicado: (2021)

Inhibition of a Microbiota-Derived Peptide Ameliorates Established Acute Lung Injury
por: Fridman D'Alessandro, Valeria, et al.
Publicado: (2023)

Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
por: Nakamura, Yuki, et al.
Publicado: (2018)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts
por: Chao, Shih-Chun, et al.
Publicado: (2011)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m1oqli6nfmp5mjklthnmlc239q